Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy. Here's a look at the most recent high-yield dividend stock ratings from the most accurate Wall Street analysts, according to Benzinga's Analyst Stock Ratings.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

Organon & Co. (NYSE: OGN)

• Dividend Yield: 5.58%
• Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and cut the price target from $26 to $25 on May 8, 2023. This analyst has an accuracy rate of 65%.
• B of A Securities analyst Jason Gerberry downgraded the stock from Buy to Neutral and slashed the price target from $40 to $37 on Aug. 5, 2022. This analyst has an accuracy rate of 70%.
• Recent News: Organon reported worse-than-expected first-quarter adjusted EPS and sales results..

AbbVie Inc. (NYSE: ABBV)

• Dividend Yield: 4.37%
• Wolfe Research analyst Tim Anderson downgraded the stock from Outperform to Peer Perform on Feb. 22, 2023. This analyst has an accuracy rate of 73%.
• SVB Leerink analyst David Risinger upgraded the stock from Underperform to Market Perform rating and raised the price target from $135 to $153 on Feb. 10, 2023. This analyst has an accuracy rate of 78%.
• Recent News: AbbVie announced reimbursement for VRAYLAR for the treatment of schizophrenia under Non-Insured Health Benefits (NIHB) Program.

Amgen Inc. (NASDAQ: AMGN)

• Dividend Yield: 3.85%
• SVB Leerink analyst David Risinger maintained a Market Perform rating and cut the price target from $282 to $267 on Feb. 2, 2023. This analyst has an accuracy rate of 78%.
• Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and cut the price target from $285 to $275 on Feb. 1, 2023. This analyst has an accuracy rate of 74%.
• Recent News: Amgen announced new research examining use of Otezla (Apremilast) in Psoriatic Arthritis.

Read More: Nvidia, Coinbase And 2 Other Stocks Insiders Are Selling